NICHOLAS PASHOS, PhD
2017 Graduate | Founder/CEO, Inventor of BioAesthetics
Nick is a New Hampshire native. He attended Drexel University, located in Philadelphia, PA, where he earned a B.S. in biomedical engineering with a concentration in biomaterials and tissue engineering. Nick is interested in pursuing regenerative medicine research. He was most attracted to the IGERT Bioinnovation Program for its research initiatives, and its crossover to business and FDA through coursework and externship opportunities.
ALEXEJ GOSSMAN, PhD
2018 Graduate | FDA –Staff Fellow at the FDA/CDRH/OSEL/DIDS
Before coming to New Orleans Alexej spent the first 12 years of his life in the Western Siberia region of Russia, and the subsequent 12 years in Germany, where he also received a Bachelor of Science degree in mathematics with a philosophy minor from Technische Universität Darmstadt in 2012. He originally came to Tulane as an exchange student, fell in love with New Orleans, and stayed for his PhD education. At Tulane, Alexej completed a Master's degree in statistics in 2014, spent several years in the Mathematics PhD program, and in Spring 2017 decided to join the interdisciplinary Bioinnovation PhD Program. As part of his PhD research he is working on novel statistical and machine learning approaches for feature selection and prediction for big and high-dimensional datasets that arise from genomic and neuroimaging studies, with a particular focus on understanding how false positive findings can arise and figuring out how they can be avoided within those contexts. He has two cats and two dogs, and in his free time he likes to play music, exercise, and sharpen his skills in computer programming, data analysis and visualization.
KAROLINA KOSAKOWSKA, PhD
2018 Graduate | Development Scientist, Formulation Technology at Casebia Therapeutics
Karolina is from Stamford, CT by way of the rich farmlands of Poland. She completed her Bachelor's degree in Chemistry at Smith College in 2011 where she did extensive organic chemistry research in small molecule synthesis. Karolina was able to develop her interest in medicinal chemistry through an internship at Biogen IDEC in cancer drug synthesis. After vacationing in New Orleans as an undergraduate, Karolina was smitten by the city and its charms. She is now proud to call New Orleans home, where she is currently exploring her interest in curing meats.
DAVID TULMAN, PhD
2018 Graduate | Chief Clinical Officer at InstaPath
David grew up in Columbus, Ohio and earned a B.S. in Biology from The Ohio State University in 2010. He then worked at The Ohio State University Medical Center in the department of Anesthesiology on phase II, III, and IV clinical trials focused on neurotoxicity of anesthetics, intraoperative medical devices, and post-surgical outcomes. This research inspired pursuit of studies in translational investigations of critical illnesses. Specifically, David plans to continue research in the areas of pharmacological interventions for improved patient outcomes and applications of novel medical technology. The Tulane IGERT Bioinnovation Program offers the opportunity to bridge research initiatives, business ventures, and regulatory understanding via an internship with the FDA.
DEREK DASHTI, PhD
2019 Graduate | Founder, Inventor & CEO of D&P Bioinnovations
Derek grew up in California and obtained both his B.S. and M.S. in Bioengineering at UC Berkeley and UC San Francisco. His undergraduate and graduate research focused on regenerative medicine - specifically on stem cell tissue engineering of the muscle and heart. Derek's masters training further emphasized translational medicine and understanding the regulatory processes to develop novel regenerative medical therapies from "bench to bedside." The IGERT Bioinnovation PhD program at Tulane extends his education in the innovative field of translational medicine. Distinctively, it will elucidate the mechanisms and resources he needs to succeed in expediting his research interests to the biotech market. Through Derek's IGERT training, he aims to not only be a successful scientist, but also to become well versed in advancing novel biomedical therapies from academia to industry.
SAMANTHA KURTZ, PhD
2019 Graduate | Consultant at Molekule Consulting
Samantha was raised in Little Rock, Arkansas. She attended the University of Arkansas in Fayetteville, AR and earned a B.S. in Biology in 2012 and a M.S. in Biomedical Engineering in 2014. Her master's thesis focused on the development and characterization of a whole cell breast cancer vaccine. This research sparked her interest in vaccine development, immunotherapy, and various cancer treatments. Samantha was attracted to the IGERT Bioinnovation program due to the integration of engineering and business coursework alongside invaluable hands-on experiences through the FDA internship and business competitions.
JESSICA MOTHERWELL, PhD
2019 Graduate | Postdoctoral Fellow Tulane Department of Medicine and Surgery
Jessica is southern California native. She earned her B.S. in Biomedical Engineering with a specialization in nanotechnology from UC Irvine in 2014. Her undergraduate research focused on prevascularizing implantable three-dimensional tissues for applications in regenerative medicine and tissue engineering. Jessica is interested in pursuing research in translational medicine with an emphasis in cardiovascular engineering. She was drawn to Tulane’s IGERT Bioinnovation program because of the integration between research, business and regulatory processes. Through the valuable experiences and skills Jessica will gain from the program, she plans to become a successful scientist in the biomedical industry.
DEVON BOWSER, PhD
Devon Bowser is a native of South Carolina. She received a Bachelor of Science degree in Bioengineering with a specialization in biomaterials from Clemson University in May 2013. Her undergraduate research in the field of tissue engineering and regenerative medicine focused on tissue engineered vascular grafts. She has since transitioned to working in a neural microengineering lab where her project is focused on the development of a CNS nerve-on-a-chip platform to be used in preclinical screening of drug compounds. The implementation of this type of technology in the preclinical screening stage of drug development process has the potential to decrease the cost of bringing life altering drugs to market.